Bristol-Myers Squibb Company
Phenylpyrrolidinone formyl peptide 2 receptor agonists
Last updated:
Abstract:
The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases. ##STR00001##
Status:
Grant
Type:
Utility
Filling date:
4 Mar 2019
Issue date:
9 Jun 2020